Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
Tracy Cole(Ionis Pharmaceuticals (United States)), Katrina L. Paumier(Washington University in St. Louis)
Cited by 10
Related Papers
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease
|Neurology|2018|322
The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model
|Alzheimer s & Dementia|2016|303
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
|JCI Insight|2021|136
Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model
|Annals of Neurology|2021|80